Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash from Operations (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Cash from Operations data on record, last reported at 20777000.0 in Q4 2021.

  • For Q4 2021, Cash from Operations fell 121.83% year-over-year to 20777000.0; the TTM value through Dec 2021 reached 58763000.0, down 63.91%, while the annual FY2025 figure was 264444000.0, 27.26% down from the prior year.
  • Cash from Operations reached 20777000.0 in Q4 2021 per COGT's latest filing, down from 14109000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 7575000.0 in Q3 2018 and bottomed at 20777000.0 in Q4 2021.
  • Average Cash from Operations over 4 years is 10538500.0, with a median of 9786500.0 recorded in 2019.
  • Peak YoY movement for Cash from Operations: skyrocketed 31.47% in 2020, then plummeted 121.83% in 2021.
  • A 4-year view of Cash from Operations shows it stood at 9020000.0 in 2018, then increased by 6.37% to 8445000.0 in 2019, then decreased by 10.91% to 9366000.0 in 2020, then tumbled by 121.83% to 20777000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 20777000.0 in Q4 2021, 14109000.0 in Q3 2021, and 12511000.0 in Q2 2021.